Derisking Topical Formulation Development: Manufacturing Chemist

January 29, 2021

Today the market for topical pharmaceuticals is valued at around $95 billion, with topical drug development efforts particularly focused on small molecules and biologics. Forecast to grow by $70 billion during the next 4–5 years, this is a fast-moving area in which cost-effective development is essential.

In this article, Dr Jon Lenn, Chief Technology Officer, and Professor Marc Brown, Chief Scientific Officer at MedPharm explore how multifactorial disease models can be deployed to make topical formulation development more efficient and increase their chances of success.

Read the full article in Manufacturing Chemist here.

About MedPharm
MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm is experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognised for their scientific rigour by regulators and investors. MedPharm has fully established Centers of Excellence in the USA and the UK.